MedTrace Logo

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

NCT02155803 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-01-26

No results posted yet for this study

Summary

ACTHAR Gel has activity in sarcoidosis associated hypercalciuria and calcium dysregulation.

Conditions

  • Sarcoidosis
  • Hypercalcemia Due to Sarcoidosis

Interventions

DRUG

ACTHAR Gel (adrenocorticotropic hormone)

ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks

Sponsors & Collaborators

  • Albany Medical College

    lead OTHER

Principal Investigators

  • Marc A Judson, MD · Albany Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-06-30
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02155803 on ClinicalTrials.gov